| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e70e294d174f09278f26545f613f356
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e0af09446a19d9558aeccbfc6a05274
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0d29524ec469fe9310a7dc2a5370964
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02fab4ba518367814c3b0d40c129da8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
1997-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bca0052a4987708c3d9ced88201a308d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e2890c45f3bfc2cd724f3a13b95237f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5132ed82a7f1d4c0c04f3aaf527dea7e |
| publicationDate |
1999-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9903451-A1 |
| titleOfInvention |
Pharmaceutical formulations for oral administration |
| abstract |
Pharmaceutical formulations for oral administration which reduce the local gastrointestinal irritating effects of an active ingredient known to exibit such effects comprise the active ingredient, for example, a non-steroidal anti-inflammatory drug, dispersed in a milk protein, such as casein or the sodium salt thereof. These formulations are designed to exhibit a cytoprotective effect in the gastrointestinal tract. Controlled release of active ingredient can be achieved with the pharmaceutical formulations if the active ingredient and the milk protein are dispersed in a cellulose ether. The controlled release pharmaceutical formulations exhibit a substantially linear or positively curved release profile. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03045416-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007097936-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03045416-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007097936-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8431221-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10610469-B2 |
| priorityDate |
1997-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |